Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023)

Merck Sharp & Dohme (MSD)

Status

Conditions: HIV Infections

Treatments: Drug: raltegravir

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT00377065

MK0518-023

2006_031

0518-023

Details and patient eligibility

About

This is a treatment use study to provide early access to MK0518 for the treatment of HIV-1 infection in patients who have limited or no treatment options due to virological failure, resistance, or intolerance to multiple antiretroviral regimens. Enrollment in this study is patient driven. Investigators are not proactively assigned. There is no target sample size and duration of the study is indefinite. For information on how to enroll in the study, see link below.

Sex: All

Ages: 16+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• HIV positive patients who have limited or no treatment options and have documented resistance

Exclusion criteria

• Patient has previously been on MK0518 therapy